<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004156</url>
  </required_header>
  <id_info>
    <org_study_id>N181</org_study_id>
    <nct_id>NCT04004156</nct_id>
  </id_info>
  <brief_title>Safety Study for An Artificial Disc Replacement to Treat Chronic Low Back Pain</brief_title>
  <official_title>Safety Study for An Artificial Disc Replacement &quot;PerQdisc Nucleus Replacement Device&quot; NUCLEUS 181</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spinal Stabilization Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spinal Stabilization Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective, open-label, multi-center study that will collect safety&#xD;
      data for the minimally invasive PerQdisc Nucleus Replacement Device deployed to reduce&#xD;
      chronic low back pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective, open-label, multi-center study that will collect safety&#xD;
      data for the minimally invasive PerQdisc Nucleus Replacement Device (NRD). The NRD is used&#xD;
      for surgical replacement of a single nucleus pulposus between spinal lumbar discs L1-S1 using&#xD;
      an anterior or lateral transpsoas approach. Currently the surgical gold standard involves&#xD;
      spinal fusion of the affected vertebral bodies, reducing range of motion and increasing&#xD;
      stress on other vertebral bodies. The goal of nucleus replacement is to reduce chronic low&#xD;
      back pain by maintaining disc height while preserving range of motion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open label study. Patients that are unable to receive an implant due to intraoperative exclusion will receive standard of care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of revision surgery at the treated level</measure>
    <time_frame>90 days</time_frame>
    <description>Number of patients requiring surgeries to revise the implanted level in the spine divided by the total number of implant surgeries. Express in percentage (0-100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of expulsion</measure>
    <time_frame>90 Days</time_frame>
    <description>The rate of device expulsion. The number of patients determined to have expulsed devices divided by the total number of patients receiving implants.Expressed in percentage (0-100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of new herniation at the treated level as determined by MRI</measure>
    <time_frame>90 days</time_frame>
    <description>Herniation will be determine by MRI. A herniation will be defined as violation of the intervertebral annulus, including expulsion of nucleus material. The response will be yes/no as assessed by the radiologist. Rate will be determined by total number of herniations divided by the total number of implanted devices. Expressed in percentage (0-100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of new radiculopathy</measure>
    <time_frame>90 days</time_frame>
    <description>New complaint of leg pain will be recorded as a yes/no response. Any complaint of new radiculopathy not seen preoperatively. Expressed as total number of new radiculopathy complaints divided by total number of patients. Expressed in percentage (0-100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI assessment of the endplate Modic changes.</measure>
    <time_frame>90 days</time_frame>
    <description>Changes to vertebral endplates will be assigned based on Modic classification of I,II or III comparing preoperative grade to grade at 90 days. Possible scores are I,II or III</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of surgical procedure technical success</measure>
    <time_frame>90 days</time_frame>
    <description>The number of devices successfully implanted divided by the number of successfully devices implanted + unsuccessful implants. Output will be in percentage (0-100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in degree of disability as measured by the Oswestry Disability Index (ODI)</measure>
    <time_frame>90 days</time_frame>
    <description>Change in absolute Oswestry Index score at 90 days compared to the preoperative score, range is 0-100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in back pain as measured by 10-centimeter Visual Analog Scale (VAS)</measure>
    <time_frame>90 days</time_frame>
    <description>Change in the Visual Analogue Scale (VAS) for back and leg pain on a scale of 0-10 cm comparing preoperative scores to 90 days post-operative.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Chronic Low-back Pain</condition>
  <arm_group>
    <arm_group_label>Nucleus Replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PerQdisc® Nucleus Replacement Device.</intervention_name>
    <description>All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.</description>
    <arm_group_label>Nucleus Replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is skeletally mature and between 22 and 60 years of age.&#xD;
&#xD;
          -  Patient has degenerative disc disease (DDD) at a single level between L1 and S1 as&#xD;
             confirmed by:History and clinical findings suggestive of symptomatic DDD, Darkened&#xD;
             disc on MRI in T2 weighted images, and decreased disc height (decreased greater than 2&#xD;
             mm compared to adjacent cranial or caudal disc height) with minimum disc height of 6&#xD;
             mm.&#xD;
&#xD;
          -  Patient has pre-operative back pain VAS score of greater than or equal to 4 (0-10&#xD;
             scale).&#xD;
&#xD;
          -  Patient has pre-operative Oswestry Low Back Disability score of greater than or equal&#xD;
             to 40 (0-100 scale).&#xD;
&#xD;
          -  Patient has received conservative (non-surgical) treatment for back pain for a minimum&#xD;
             of 6 months.&#xD;
&#xD;
          -  Patient has signed the approved Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has had prior lumbar spine surgery.&#xD;
&#xD;
          -  Patient has motion of less than 3 degrees on pre-operative lateral flexion/extension&#xD;
             radiographs.&#xD;
&#xD;
          -  Patient has ankylosing spondylitis or other spondyloarthropathy.&#xD;
&#xD;
          -  Patient has isthmic spondylolisthesis or degenerative spondylolisthesis greater than 2&#xD;
             mm.&#xD;
&#xD;
          -  Patient has congenital stenosis or epidural lipomatosis.&#xD;
&#xD;
          -  Patient has significant facet disease.&#xD;
&#xD;
          -  Patient has any known active malignancy.&#xD;
&#xD;
          -  Patient has previously undergone immunosuppressive therapy.&#xD;
&#xD;
          -  Patient has active local or system infection.&#xD;
&#xD;
          -  Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus,&#xD;
             or other autoimmune disease, including AIDS, ARC and HIV&#xD;
&#xD;
          -  Patient has diabetes mellitus (Type 1 or 2), requiring daily insulin management.&#xD;
&#xD;
          -  Patient has osteopenia of the spine (T-score less than 1.0). All females 45 years of&#xD;
             age or older and all males 50 or older should have a DEXA scan to confirm this&#xD;
             exclusion.&#xD;
&#xD;
          -  Patient has morbid obesity defined as body mass index (BMI) more than 40 or a weight&#xD;
             of more than 45 kg (100 lbs) over ideal body weight.&#xD;
&#xD;
          -  Patient is pregnant or plans to become pregnant during the course of the study.&#xD;
&#xD;
          -  Patient has a known allergy to silicone (polymer and balloon material) or barium&#xD;
             sulfate (polymer).&#xD;
&#xD;
          -  Patient participated in another investigational drug or device study within the past&#xD;
             30 days.&#xD;
&#xD;
          -  Patient belongs to a vulnerable population or has a condition such that his/her&#xD;
             ability to provide informed consent, comply with follow-up requirements, or provide&#xD;
             self assessments is compromised (e.g. developmentally disables, prisoner, chronic&#xD;
             alcohol/ substance abuser)&#xD;
&#xD;
          -  Patient has a disc herniation&#xD;
&#xD;
          -  Patient has a Schmorl's node in the level to be treated&#xD;
&#xD;
        Intraoperative exclusion criteria:&#xD;
&#xD;
          -  Protrusion of the 20A imaging balloon up to or beyond the outer margin of the vertebra&#xD;
             during the imaging steps.&#xD;
&#xD;
          -  Patient has a violated endplate.&#xD;
&#xD;
          -  Patient has a disc space that is too narrow.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hess, MD</last_name>
    <role>Study Chair</role>
    <affiliation>London Spine Clinic/ATOS-Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donauisar Klinikum Deggendorf</name>
      <address>
        <city>Deggendorf</city>
        <zip>94469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Degenerative Disc Disease</keyword>
  <keyword>DDD</keyword>
  <keyword>Chronic Low-back Pain</keyword>
  <keyword>Low Back Pain</keyword>
  <keyword>Nucleus Replacement Device</keyword>
  <keyword>Nucleus Pulposus</keyword>
  <keyword>Disc Replacement</keyword>
  <keyword>Back pain</keyword>
  <keyword>Leg pain</keyword>
  <keyword>Lumbar Spinal Fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

